ReviewCancer biology & therapy2026
Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma.
Review in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a prognostic prediction model incorporatingJournal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is one of the most prevalent malignant tumors of the digestive tract, with esophageal squamous cell carcinoma (ESCC) as its main histological type. In recent years, immunotherapeutic regimens centered on immune checkpoint inhibitors (ICIs) have achieved remarkable efficacy in patients with advanced ESCC. However, due to the heterogeneity of the tumor immune microenvironment (TIME), the degree of clinical benefit varies among patients. This heterogeneity not only affects the biological behavior of tumors but also determines the efficacy and prognosis of immunotherapy. Therefore, exploring the interactions between tumor cells and diverse immunological components inside the TIME in ESCC, as well as how to use ICIs to reshape the TIME, may bring new therapeutic opportunities for ESCC patients. This review looks at the important aspects of TIME and immunological prediction models and explores potential therapeutic strategies targeting both, providing a theoretical basis for improving immunotherapy outcomes in ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.